Oncotelic's PDAOAI Platform Highlights Shift Toward Evidence-Based AI in Pharma

Oncotelic Therapeutics Inc. (OTCQB: OTLC) has introduced PDAOAI, an evidence-interrogation platform that indexes more than 125,000 PubMed abstracts on TGF-β signaling. The platform enables researchers to generate testable, auditable hypotheses from existing literature, contrasting with traditional black-box predictive models. This approach aligns with a broader industry shift toward transparent and reproducible AI-driven research, as regulatory agencies demand greater data integrity and traceability in pharmaceutical operations.

Recent industry coverage has placed Oncotelic alongside companies such as Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as key contributors to the pharmaceutical sector's transition toward AI-integrated operations. This recognition underscores the importance of hypothesis-first tools that reduce training-set bias and create clear chains from question to evidence to hypothesis.

The pharmaceutical industry is undergoing a structural transformation where manual processes and isolated datasets are no longer sufficient. The rapid expansion of scientific literature and heightened regulatory expectations require continuous, defensible documentation. Oncotelic's PDAOAI platform addresses these challenges by organizing and connecting large volumes of biomedical literature, allowing researchers to identify patterns and generate testable hypotheses with direct links to source evidence.

According to the company, the retrieval-and-interrogation approach of PDAOAI offers a solution to core challenges in biotech research, such as reducing training-set bias and building transparent, reproducible research workflows. This method supports the industry's shift from retrospective audits toward continuous, AI-enabled monitoring systems, as noted in the company's announcement available at ibn.fm/OTLC.

For more information about BioMedWire and its coverage of the life sciences sector, visit https://www.BioMedWire.com. BioMedWire is a specialized communications platform focusing on the latest developments in biotechnology, biomedical sciences, and life sciences, and is part of the Dynamic Brand Portfolio @IBN.